PMID- 33194599
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 10
DP  - 2020
TI  - What Multiple Myeloma With t(11;14) Should Be Classified Into in Novel Agent Era: 
      Standard or Intermediate Risk?
PG  - 538126
LID - 10.3389/fonc.2020.538126 [doi]
LID - 538126
AB  - OBJECTIVE: To investigate the prognostic value of t(11;14) for de novo multiple 
      myeloma (MM) patients in novel agent era. METHODS: A total of 455 patients with 
      fluorescence in situ hybridization (FISH), before treatments from three hospitals 
      in China, were included in the study. All patients received autologous stem cell 
      transplantation (ASCT) after induction therapy as consolidation. High risk (HR) 
      cytogenetics were defined as t(4;14), t(14;16), and/or del 17p. RESULTS: A total 
      of 152 patients were in the HR group. Of patients without HR cytogenetics, 55 
      were in the t(11;14) group, and 248 were in the standard risk (SR) group without 
      t(11;14). Gain in 1q21 was observed in 38.9% patients with t(11;14). There were 
      no differences in median progression free survival (PFS) and overall survival 
      (OS), respectively, between patients in the t(11;14) group and those in the SR 
      group. Patients in the t(11;14) group had the longer median PFS and OS, 
      respectively, compared with those in the HR group. Regardless of coexisting with 
      1q21 gain or not, patients in the t(11;14) group still had similar median PFS and 
      OS compared to those in the SR group. Finally, multivariate analysis indicated 
      that including 1q21 gain and bone marrow plasma cell with CD20 expression, no 
      variables were found to predict the outcome of the t(11;14) group in our cohort. 
      CONCLUSIONS: These results confirm that outcomes of t(11;14) MM are similar to 
      standard risk patients when they receive novel agent induction therapy 
      consolidated by ASCT. Gain of 1q21 coexists with t(11;14) frequently. In 
      addition, both bone marrow plasma cell with CD20 expression and 1q21 gain have no 
      impact on median PFS or OS for patients with t(11;14).
CI  - Copyright (c) 2020 Gao, Du, Liu, Zhou, Zhang, Jian, Yang, Wang, Tian, Li, Wu, Fu, 
      Li and Chen.
FAU - Gao, Wen
AU  - Gao W
AD  - Department of Hematology, Myeloma Research Center of Beijing, Beijing Chao-Yang 
      Hospital, Capital Medical University, Beijing, China.
FAU - Du, Juan
AU  - Du J
AD  - Department of Hematology, The Myeloma & Lymphoma Center, Changzheng Hospital, The 
      Second Military Medical University, Shanghai, China.
FAU - Liu, Junru
AU  - Liu J
AD  - Department of Hematology, The First Affiliated Hospital of Sun Yat-sen 
      University, Guangzhou, China.
FAU - Zhou, Huixing
AU  - Zhou H
AD  - Department of Hematology, Myeloma Research Center of Beijing, Beijing Chao-Yang 
      Hospital, Capital Medical University, Beijing, China.
FAU - Zhang, Zhiyao
AU  - Zhang Z
AD  - Department of Hematology, Myeloma Research Center of Beijing, Beijing Chao-Yang 
      Hospital, Capital Medical University, Beijing, China.
FAU - Jian, Yuan
AU  - Jian Y
AD  - Department of Hematology, Myeloma Research Center of Beijing, Beijing Chao-Yang 
      Hospital, Capital Medical University, Beijing, China.
FAU - Yang, Guangzhong
AU  - Yang G
AD  - Department of Hematology, Myeloma Research Center of Beijing, Beijing Chao-Yang 
      Hospital, Capital Medical University, Beijing, China.
FAU - Wang, Guorong
AU  - Wang G
AD  - Department of Hematology, Myeloma Research Center of Beijing, Beijing Chao-Yang 
      Hospital, Capital Medical University, Beijing, China.
FAU - Tian, Ying
AU  - Tian Y
AD  - Department of Hematology, Myeloma Research Center of Beijing, Beijing Chao-Yang 
      Hospital, Capital Medical University, Beijing, China.
FAU - Li, Yanchen
AU  - Li Y
AD  - Department of Hematology, Myeloma Research Center of Beijing, Beijing Chao-Yang 
      Hospital, Capital Medical University, Beijing, China.
FAU - Wu, Yin
AU  - Wu Y
AD  - Department of Hematology, Myeloma Research Center of Beijing, Beijing Chao-Yang 
      Hospital, Capital Medical University, Beijing, China.
FAU - Fu, Weijun
AU  - Fu W
AD  - Department of Hematology, The Myeloma & Lymphoma Center, Changzheng Hospital, The 
      Second Military Medical University, Shanghai, China.
FAU - Li, Juan
AU  - Li J
AD  - Department of Hematology, The First Affiliated Hospital of Sun Yat-sen 
      University, Guangzhou, China.
FAU - Chen, Wenming
AU  - Chen W
AD  - Department of Hematology, Myeloma Research Center of Beijing, Beijing Chao-Yang 
      Hospital, Capital Medical University, Beijing, China.
LA  - eng
PT  - Journal Article
DEP - 20201026
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC7649769
OTO - NOTNLM
OT  - 1q21 gain
OT  - autologous stem cell transplantation
OT  - multiple myeloma
OT  - novel agent
OT  - t(11;14)
EDAT- 2020/11/17 06:00
MHDA- 2020/11/17 06:01
PMCR- 2020/01/01
CRDT- 2020/11/16 08:52
PHST- 2020/04/22 00:00 [received]
PHST- 2020/08/20 00:00 [accepted]
PHST- 2020/11/16 08:52 [entrez]
PHST- 2020/11/17 06:00 [pubmed]
PHST- 2020/11/17 06:01 [medline]
PHST- 2020/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2020.538126 [doi]
PST - epublish
SO  - Front Oncol. 2020 Oct 26;10:538126. doi: 10.3389/fonc.2020.538126. eCollection 
      2020.